AstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer Patients
By Anthony O. Goriainoff
AstraZeneca said Monday that its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial.
The London-listed pharmaceutical giant said the first Phase 3 results showed a statistically-significant improvement in progression-free survival versus standard chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior therapy.
The company said datopotamab deruxtecan's safety profile is consistent with previous clinical trials and that no new safety signals identified.
"These first Phase 3 trial results from the datopotamab deruxtecan clinical program provide compelling evidence for the potential role this... antibody drug conjugate can play in treating patients with lung cancer," the company said.
Datopotamab deruxtecan is being jointly developed by AstraZeneca and Daiichi Sankyo.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
July 03, 2023 02:35 ET (06:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom